Medpace Holdings, Inc. Operating Lease, Payments
Medpace Holdings, Inc. (MEDP) reported Operating Lease, Payments of $12.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-07-23
- Medpace Holdings, Inc. operating lease, payments for the quarter ending 2026-06-30 was $7.31M, a 14.97% increase year-over-year.
- Medpace Holdings, Inc. operating lease, payments for the quarter ending 2026-03-31 was $5.51M, a 17.33% decline year-over-year.
- Medpace Holdings, Inc. operating lease, payments for the quarter ending 2025-12-31 was $7.15M, a 15.69% increase year-over-year.
- Medpace Holdings, Inc. operating lease, payments for the quarter ending 2025-09-30 was $5.71M, a 22.46% increase year-over-year.
- Medpace Holdings, Inc. operating lease, payments for fiscal 2025 was $25.89M, a 15.51% increase from fiscal 2024.
- Medpace Holdings, Inc. operating lease, payments for fiscal 2024 was $22.41M, a 13.03% increase from fiscal 2023.
- Medpace Holdings, Inc. operating lease, payments for fiscal 2023 was $19.83M, a 16.63% increase from fiscal 2022.
- Medpace Holdings, Inc. operating lease, payments for fiscal 2022 was $17.00M, a 4.52% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $12.82M 10-Q · filed 2026-07-23 | $19.97M derived: sum of 3 quarters · filed 2026-07-23 | $25.69M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $5.51M 10-Q · filed 2026-04-23 | $12.66M derived: sum of 2 quarters · filed 2026-04-23 | $18.37M derived: sum of 3 quarters · filed 2026-04-23 | $24.73M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $12.87M derived: sum of 2 quarters · filed 2026-02-10 | $19.23M derived: sum of 3 quarters · filed 2026-07-23 | $25.89M 10-K · filed 2026-02-10 |
| 2025-09-30 | $5.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $12.07M derived: sum of 2 quarters · filed 2026-07-23 | $18.74M 10-Q · filed 2025-10-23 | $24.92M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $6.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $13.02M 10-Q · filed 2026-07-23 | $19.20M derived: sum of 3 quarters · filed 2026-07-23 | $23.87M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $6.66M 10-Q · filed 2026-04-23 | $12.84M derived: sum of 2 quarters · filed 2026-04-23 | $17.51M derived: sum of 3 quarters · filed 2026-04-23 | $22.93M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $6.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $10.85M derived: sum of 2 quarters · filed 2026-02-10 | $16.26M derived: sum of 3 quarters · filed 2026-02-10 | $22.41M 10-K · filed 2026-02-10 |
| 2024-09-30 | $4.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $10.08M derived: sum of 2 quarters · filed 2025-10-23 | $16.23M 10-Q · filed 2025-10-23 | $21.18M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $5.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-22 | $11.56M 10-Q · filed 2025-07-22 | $16.51M derived: sum of 3 quarters · filed 2026-02-10 | $21.80M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $6.15M 10-Q · filed 2025-04-22 | $11.10M derived: sum of 2 quarters · filed 2026-02-10 | $16.38M derived: sum of 3 quarters · filed 2026-02-10 | $20.63M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $10.23M derived: sum of 2 quarters · filed 2026-02-10 | $14.48M derived: sum of 3 quarters · filed 2026-02-10 | $19.83M 10-K · filed 2026-02-10 |
| 2023-09-30 | $5.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-22 | $9.53M derived: sum of 2 quarters · filed 2024-10-22 | $14.88M 10-Q · filed 2024-10-22 | $19.84M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-23 | $9.60M 10-Q · filed 2024-07-23 | $14.56M derived: sum of 3 quarters · filed 2025-02-11 | $18.34M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $5.35M 10-Q · filed 2024-04-23 | $10.31M derived: sum of 2 quarters · filed 2025-02-11 | $14.10M derived: sum of 3 quarters · filed 2025-02-11 | $18.55M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $8.74M derived: sum of 2 quarters · filed 2025-02-11 | $13.20M derived: sum of 3 quarters · filed 2025-02-11 | $17.00M 10-K · filed 2025-02-11 |
| 2022-09-30 | $3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-24 | $8.24M derived: sum of 2 quarters · filed 2023-10-24 | $12.04M 10-Q · filed 2023-10-24 | $16.46M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $4.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $8.26M 10-Q · filed 2023-07-25 | $12.68M derived: sum of 3 quarters · filed 2024-02-13 | $16.34M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $3.81M 10-Q · filed 2023-04-25 | $8.22M derived: sum of 2 quarters · filed 2024-02-13 | $11.89M derived: sum of 3 quarters · filed 2024-02-13 | $16.65M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $8.08M derived: sum of 2 quarters · filed 2024-02-13 | $12.84M derived: sum of 3 quarters · filed 2024-02-13 | $16.27M 10-K · filed 2024-02-13 |
| 2021-09-30 | $3.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $8.43M derived: sum of 2 quarters · filed 2022-10-25 | $11.85M 10-Q · filed 2022-10-25 | $16.48M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $4.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-26 | $8.19M 10-Q · filed 2022-07-26 | $12.81M derived: sum of 3 quarters · filed 2023-02-14 | $16.03M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $3.42M 10-Q · filed 2022-04-26 | $8.05M derived: sum of 2 quarters · filed 2023-02-14 | $11.27M derived: sum of 3 quarters · filed 2023-02-14 | $14.78M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $7.84M derived: sum of 2 quarters · filed 2023-02-14 | $11.36M derived: sum of 3 quarters · filed 2023-02-14 | $13.96M 10-K · filed 2023-02-14 |
| 2020-09-30 | $3.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-26 | $6.73M derived: sum of 2 quarters · filed 2021-10-26 | $9.33M 10-Q · filed 2021-10-26 | $12.12M derived: sum of 4 quarters · filed 2021-10-26 |
| 2020-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27 | $6.11M 10-Q · filed 2021-07-27 | $8.90M derived: sum of 3 quarters · filed 2021-07-27 | $11.20M derived: sum of 4 quarters · filed 2021-07-27 |
| 2020-03-31 | $2.60M 10-Q · filed 2021-04-27 | $5.39M derived: sum of 2 quarters · filed 2021-04-27 | $7.69M derived: sum of 3 quarters · filed 2021-04-27 | $10.16M derived: sum of 4 quarters · filed 2021-04-27 |
| 2019-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $5.09M derived: sum of 2 quarters · filed 2021-02-16 | $7.56M derived: sum of 3 quarters · filed 2021-02-16 | $9.77M 10-K · filed 2021-02-16 |
| 2019-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $4.76M derived: sum of 2 quarters · filed 2020-10-27 | $6.98M 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | $4.69M 10-Q · filed 2020-07-28 | ||
| 2019-03-31 | $2.22M 10-Q · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |